From JPMA From the Chairman's Press Conference

On June 17, 2020, the "Chairman's Press Conference" of the Pharmaceutical Manufacturers Association of Japan was held at Hotel Metropolitan Edmont (Chiyoda-ku, Tokyo), where the "FY2020 Activities Policy of the Pharmaceutical Manufacturers Association of Japan", "Proposals by the Pharmaceutical Manufacturers Association of Japan for the Creation of Infectious Drugs and Vaccines", "Proposals for the Framework Policy 2020", and "Progress of the Pharmaceutical Manufacturers Association of Japan Policy Proposal 2019" were explained. The following items were explained.

The recent new type of coronavirus infection has quickly spread throughout the world, paralyzing economic and social activities in countries around the world and becoming a serious social problem on a global scale. In this situation, therapeutic drugs and vaccines are the key to early containment of the infection and economic recovery, and pharmaceutical companies are promoting research and development to create safe and effective new therapeutic drugs and vaccines, as well as utilizing existing drugs, for the treatment and prevention of this infectious disease.

Based on the experience of this pandemic, the Pharmaceutical Manufacturers Association of Japan (PMAJ) has grasped the challenges of countermeasures against infectious diseases and formulated the "PMAJ Proposal for the Creation of New Drugs and Vaccines to Treat Infectious Diseases" with recommendations to overcome future infectious disease outbreaks.

(From the June 17 press conference by the head of the Pharmaceutical Manufacturers Association of Japan)